The purpose of this study is to evaluate the pharmacokinetics and safety of oral administration of BR9001 compared with BR900A in healthy subjects

This is an open-label, randomized, crossover study to evaluate the pharmacokinetics and safety. Within each period, randomized subjects will be take 2 dosing regimens that BR9001 or BR900A.

Inclusion Criteria:

• Adults 19-50 years of age
• Body mass index (BMI) ≥ 18.5 and ≤ 27.0 kg/m^2 at screening
• Medically healthy with no clinically significant medical history
• No clinically significant result with laboratory test including chemistry, serum, urine test within 3 weeks in prior to administration of investigational product
• Understands the study procedures in the Informed consent form (ICF), and be willing and able to comply with the protocol

Exclusion Criteria:

• History or presence of clinically significant medical or psychiatric condition or disease.
• Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).
• Creatinint clearance < 80 mL/min (using Cockcroft-Gault) at screening.
• Whole blood donation within a 2 months prior to the first dose of study drug.
• Participation in another clinical trial or bioequivalence study within 12 weeks prior to the first dose of study drug(s).